Evidence map›Paper›PMID 24649369›Full record

ReviewSleep disorders2014

Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness.

Joseph V Pergolizzi, Robert Taylor, Robert B Raffa, Srinivas Nalamachu, Maninder Chopra

Open access · hybridAbstract readReview
In one paragraph

Review in Sleep disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Joseph V PergolizziDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA ; Department of Anesthesiology, Georgetown University School of Medicine, Washington, DC 20057, USA ; Department of Pharmacology, School of Medicine in Philadelphia, Temple University, PA 19140, USA.
Robert TaylorNEMA Research, Inc., Naples, FL 34108, USA.
Robert B RaffaSchool of Pharmacy, Temple University, Philadelphia, PA 19140, USA.
Srinivas NalamachuKansas University Medical Center, Kansas City, KS 66160, USA ; International Clinical Research, Leawood, KS 66211, USA.ORCID 0000-0002-5854-7549
Maninder ChopraKirax Pharmaceuticals, Bonita Springs, FL 34134, USA.
Johns Hopkins University · USNema Research (United States) · USTemple University · USUniversity Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinations of these and can lead to poor health and quality of life problems. A subtype of sleep-maintenance insomnia is middle-of-the-night wakefulness, a relatively common occurrence. Zolpidem, a nonbenzodiazepine benzodiazepine receptor agonist, allosterically modulates an ion channel and increases the influx of Cl(-), thereby dampening the effect of excitatory (sleep disrupting) input. Recently, product label changes to some zolpidem containing products have been implemented by the FDA in order to reduce the risk associated with their morning after residual side effects. A new formulation of zolpidem tartrate (Intermezzo) sublingual tablet, an approved product indicated exclusively for the treatment of middle-of-the-night wakefulness and difficulty returning to sleep, did not have its label changed. We present a short summary of its basic science and clinical attributes in light of the recent regulatory changes for zolpidem products.

Identifiers

PMID24649369
PMCPMC3932650
OpenAlexW2037207387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.